PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Haoyang Zhang

Union Hospital

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · JOURNAL ARTICLE

Lipid metabolic reprogramming in NSCLC: mechanisms, microenvironment crosstalk, and therapeutic opportunities

Journal of Translational Medicine

A phase 1 study reporting a preliminary signal of activity in a molecular subtype (KRAS-mutant NSCLC, n=11) with a small sample, surrogate endpoint (progression-free status at 12 weeks), and no established clinical efficacy in unselected patients.

PreliminaryShengze Chen Pancreatic Function and Diabetes Shuang You

Reported

Progression-free at >12 weeks, KR…64%

Sample size, KRAS-mutant11

Progression-free at >12 weeks, KR…0%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support